These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35099616)

  • 1. Competitive blocking of LRP4-sclerostin binding interface strongly promotes bone anabolic functions.
    Katchkovsky S; Chatterjee B; Abramovitch-Dahan CV; Papo N; Levaot N
    Cell Mol Life Sci; 2022 Jan; 79(2):113. PubMed ID: 35099616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo.
    Choi HY; Dieckmann M; Herz J; Niemeier A
    PLoS One; 2009 Nov; 4(11):e7930. PubMed ID: 19936252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.
    Ellies DL; Viviano B; McCarthy J; Rey JP; Itasaki N; Saunders S; Krumlauf R
    J Bone Miner Res; 2006 Nov; 21(11):1738-49. PubMed ID: 17002572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lrp4 expression by adipocytes and osteoblasts differentially impacts sclerostin's endocrine effects on body composition and glucose metabolism.
    Kim SP; Da H; Li Z; Kushwaha P; Beil C; Mei L; Xiong WC; Wolfgang MJ; Clemens TL; Riddle RC
    J Biol Chem; 2019 Apr; 294(17):6899-6911. PubMed ID: 30842262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-deletion of Lrp5 and Lrp6 in the skeleton severely diminishes bone gain from sclerostin antibody administration.
    Lim KE; Bullock WA; Horan DJ; Williams BO; Warman ML; Robling AG
    Bone; 2021 Feb; 143():115708. PubMed ID: 33164872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.
    Li X; Zhang Y; Kang H; Liu W; Liu P; Zhang J; Harris SE; Wu D
    J Biol Chem; 2005 May; 280(20):19883-7. PubMed ID: 15778503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function.
    Leupin O; Piters E; Halleux C; Hu S; Kramer I; Morvan F; Bouwmeester T; Schirle M; Bueno-Lozano M; Fuentes FJ; Itin PH; Boudin E; de Freitas F; Jennes K; Brannetti B; Charara N; Ebersbach H; Geisse S; Lu CX; Bauer A; Van Hul W; Kneissel M
    J Biol Chem; 2011 Jun; 286(22):19489-500. PubMed ID: 21471202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Additional Lrp4 High Bone Mass Mutation Mitigates the Sost-Knockout Phenotype in Mice by Increasing Bone Remodeling.
    Hendrickx G; Boudin E; Mateiu L; Yorgan TA; Steenackers E; Kneissel M; Kramer I; Mortier G; Schinke T; Van Hul W
    Calcif Tissue Int; 2024 Feb; 114(2):171-181. PubMed ID: 38051321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesd is a universal inhibitor of Wnt coreceptors LRP5 and LRP6 and blocks Wnt/beta-catenin signaling in cancer cells.
    Lu W; Liu CC; Thottassery JV; Bu G; Li Y
    Biochemistry; 2010 Jun; 49(22):4635-43. PubMed ID: 20446724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels.
    Chang MK; Kramer I; Huber T; Kinzel B; Guth-Gundel S; Leupin O; Kneissel M
    Proc Natl Acad Sci U S A; 2014 Dec; 111(48):E5187-95. PubMed ID: 25404300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling.
    van Dinther M; Zhang J; Weidauer SE; Boschert V; Muth EM; Knappik A; de Gorter DJ; van Kasteren PB; Frisch C; Mueller TD; ten Dijke P
    PLoS One; 2013; 8(4):e62295. PubMed ID: 23638027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lrp4 and Wise interplay controls the formation and patterning of mammary and other skin appendage placodes by modulating Wnt signaling.
    Ahn Y; Sims C; Logue JM; Weatherbee SD; Krumlauf R
    Development; 2013 Feb; 140(3):583-93. PubMed ID: 23293290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Domain-Specific Mutation in a Sclerosteosis Patient Suggests a Role of LRP4 as an Anchor for Sclerostin in Human Bone.
    Fijalkowski I; Geets E; Steenackers E; Van Hoof V; Ramos FJ; Mortier G; Fortuna AM; Van Hul W; Boudin E
    J Bone Miner Res; 2016 Apr; 31(4):874-81. PubMed ID: 26751728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesd binds to mature LDL-receptor-related protein-6 and antagonizes ligand binding.
    Li Y; Chen J; Lu W; McCormick LM; Wang J; Bu G
    J Cell Sci; 2005 Nov; 118(Pt 22):5305-14. PubMed ID: 16263759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies.
    Ettenberg SA; Charlat O; Daley MP; Liu S; Vincent KJ; Stuart DD; Schuller AG; Yuan J; Ospina B; Green J; Yu Q; Walsh R; Li S; Schmitz R; Heine H; Bilic S; Ostrom L; Mosher R; Hartlepp KF; Zhu Z; Fawell S; Yao YM; Stover D; Finan PM; Porter JA; Sellers WR; Klagge IM; Cong F
    Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15473-8. PubMed ID: 20713706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone.
    Williams BO; Insogna KL
    J Bone Miner Res; 2009 Feb; 24(2):171-8. PubMed ID: 19072724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sclerostin blockade inhibits bone resorption through PDGF receptor signaling in osteoblast lineage cells.
    Thouverey C; Apostolides P; Brun J; Caverzasio J; Ferrari S
    JCI Insight; 2024 May; 9(10):. PubMed ID: 38713511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational analysis of sclerostin shows importance of the flexible loop and the cystine-knot for Wnt-signaling inhibition.
    Boschert V; van Dinther M; Weidauer S; van Pee K; Muth EM; Ten Dijke P; Mueller TD
    PLoS One; 2013; 8(11):e81710. PubMed ID: 24312339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption.
    Xiong L; Jung JU; Wu H; Xia WF; Pan JX; Shen C; Mei L; Xiong WC
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3487-92. PubMed ID: 25733894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome.
    Kedlaya R; Veera S; Horan DJ; Moss RE; Ayturk UM; Jacobsen CM; Bowen ME; Paszty C; Warman ML; Robling AG
    Sci Transl Med; 2013 Nov; 5(211):211ra158. PubMed ID: 24225945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.